RATIONALE FOR THERAPY IN PATIENTS WITH PERSISTENT VIRAL INFECTIONS DURING PREGRAVID PREPARATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Pregravidpreparation is a long and complex therapeutic and diagnostic process related, among other things, to the elimination of the impact of chronic viral infections on the patient's body. A special role is played by herpetic and papillomavirus infections as a factor that increases the risk of not only a negative result of pregravid preparation, but also the development of malignant neoplasms. The effect of these viruses on the immune system as both monoinfections and mixed infections in combination with other viruses is unambiguously negative; however, it is characterized by a number of features that there is no consensus about. Objective. To comprehensively assess humoral immunity responses in women with persistent viral infections during pregravid preparation. Subjects and methods. A total of 149 young patients divided into 2 groups (a study group and a control group) according to human papillomavirus infection underwent estimation of the serum levels of cytokines (IL-10, IL-17), transforming growth factors (TGF-a, TGF-P1, TGF-P2), interferons IFN-P, IFN-y, IFN-A1 (IL-29), IFN-A3 (iL-28), metalloproteinases (mMP-2, MmP-8, MmP-9) and their tissue inhibitors (TIMP-1, TIMP-2, TIMP-3). Results. The authors established a multidirectional change in the level of pro- and anti-inflammatory cytokines in serum, as well as hyperproduction of transforming growth factors, metalloproteinases and their inhibitors. The article separately highlights the role of interferons and also discusses the potential possibility of therapy with interferon inducers in patients with persistent viral infections during pregravid preparation. Conclusion. The revealed abnormal levels of pro- and anti-inflammatory cytokines, transforming growth factors, and metalloproteinases confirm that there is a difference in the characteristics of an immune response in young women during pregravid preparation, depending on which viral infections are detected in patients. Taking into account the findings, the authors consider it possible to use interferon inducers in the treatment of patients with persistent viral infections, especially in those with mixed infections.

Full Text

Restricted Access

About the authors

Elena V. Markelova

Pacific State Medical University, Ministry of Health of the Russian Federation

Email: markev2010@mail.ru
Dr. Med. Sci., Professor, Head of the Department of Normal and Pathological Physiology 690002, Russia, Primorsky Krai, Vladivostok, Ostryakov Ave. 2

Marina S. Tulupova

Paracelsus Medical Center

Email: paracels.kdmc@yandex.ru
Cand. Med. Sci., obstetrician-gynecologist, Head physician Russia, Primorsky Krai, Vladivostok, Novoivanovskaya str., 4А

Tatyana A. Nevezhkina

Pacific State Medical University, Ministry of Health of the Russian Federation

Email: www.tanya.ru9292@mail.ru
Assistant of the Department of Normal and Pathological Physiology 690002, Russia, Primorsky Krai, Vladivostok, Ostryakov Ave. 2

Sergey V. Knysh

Pacific State Medical University, Ministry of Health of the Russian Federation

Email: sergio_knish@mail.ru
Cand. Med. Sci., Assistant of the Department of Normal and Pathological Physiology 690002, Russia, Primorsky Krai, Vladivostok, Ostryakov Ave. 2

Lyudmila S. Matyushkina

Pacific State Medical University, Ministry of Health of the Russian Federation

Email: doctor-lsm@yandex.ru
Cand. Med. Sci., Assistant professor, Head of the Department of Obstetrics and Gynecology 690002, Russia, Primorsky Krai, Vladivostok, Ostryakov Ave. 2

References

  1. Пустотина О.А. Прегравидарная подготовка. Медицинский совет. 2017; 13: 64-70. Доступно по: https://cyberleninka.ru/article/n/pregravidarnaya-podgotovka Активна на: 19.12.2020.
  2. Бахараева И.В. Современная прегравидарная подготовка: комплексный подход. РМЖ. Мать и дитя. 2017; 12: 889-93.
  3. Посисеева Л.В., Петрова У.Л. Особенности прегравидарной подготовки супружеских пар с вирусом папилломы человека и вирусом простого герпеса. Акушерство и гинекология. 2018; 5: 132-7.
  4. Посисеева Л.В. Коррекция инфекционных заболеваний в прегравидарной подготовке супружеских пар. Инфекционные болезни: новости, мнения, обучение. 2016; 4: 131-4.
  5. Маркелова Е.В., Кныш С.В., Невежкина Т.А., Байбарина Е.В. Аль фа -герпесвирусы: современный взгляд на структуру. Тихоокеанский медицинский журнал. 2017; 4: 5-9.
  6. Молочков В.А., Семенова Т.Б., Киселев В.И., Молочков А.В. Генитальные вирусные инфекции. М.: БИНОМ; 2009. 208 с.
  7. Кустова А. М., Барановская Е.И., Жаворонок С. В., Те слов а О.А. Факторы риска генитальной папилломавирусной инфекции у ВИЧ-инфицированных беременных. Репродуктивное здоровье. Восточная Европа. 2012; 5: 349-53.
  8. Кизей И.Н., Наумчик Г.А., Середа Н.Б. Современные представления об этиопатогенезе папилломавирусной инфекции. Тихоокеанский медицинский журнал. 2010; 3: 10-5.
  9. Fernandes J.V., de Medeiros Fernandes T.A., De Azevedo J.C., Cobucci R.N., DE Carvalho M.G., Andrade V.S., DE Araujo J.M. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol. Lett. 2015; 9(3): 1015-26. https://dx.doi.org/10.3892/ol.2015.2884.
  10. Li Y., Wei C., Xu H., Jia J., Wei Z., Guo R. et al. The immunoregulation of Th17 in host against intracellular bacterial infection. Mediators Inflamm. 2018; 2018: 6587296. https://dx.doi.org/10.1155/2018/6587296.
  11. Stiff A., Carson W.III. Investigations of interferonla mb da for the treatment of cancer. J. Innate Immun. 2015; 7(3): 243-50. https://dx.doi. org/10.1159/000370113.
  12. Moghimi M., Tavakoli F., Doosti M.,Ahmadi-Vasmehjani A., Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res. Notes. 2019; 12(1): 626. https://dx.doi.org/10.1186/s13104-019-4651-z.
  13. Lace M.J., Anson J.R., Klingelhutz A.J., Harada H., Taniguchi T., Bossier A.D. et al. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis. 2009; 30(8): 1336-44. https://dx.doi. org/10.1093/carcin/bgp150.
  14. Nair S., Poddar S., Shimak R., Diamond M. Interferon regulatory factor 1 protects against chikungunya virus-induced immunopathology by restricting infection in muscle cells. J. Virol. 2017; 91(22): e01419-17. https://dx.doi. org/10.1128/jvi.01419-17.
  15. Kim K., Blatt L., Taylor M. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 2000; 81(3): 695-700. https://dx.doi. org/10.1099/0022-1317-81-3-695.
  16. Day P., Thompson C., Lowy D., Schiller J. Interferon gamma prevents infectious entry of human papillomavirus 16 via an L2-dependent mechanism. J. Virol. 2017; 91(10): e00168-17. https://dx.doi.org/10.1128/jvi.00168-17.
  17. Кононова И.Н., Обоскалова Т.А., Ворошилина Е.С., Кузина Т.В. Комплексное лечение больных с ВПЧ-ассоциированной цервикальной интраэпителиальной неоплазией с использованием кавитированного раствора панавира. Российский вестник акушера-гинеколога. 2017; 17(5): 71-4
  18. Перламутров Ю.Н., Чернова Н.И., Кучеров В.А., Стовбун С.В., Сафронов Д.Ю. Эффективность препарата локального действия в комплексной терапии папилломавирусной инфекции. Клиническая дерматология и венерология. 2012; 10(3): 41-3
  19. Карахалис Л.Ю., Зуева Т.П., Петренко С.И. Оптимизация терапии дисплазий шейки матки, ассоциированных с ВПЧ-инфекцией. Проблемы репродукции. 2012; 5: 50-3
  20. Kang M., Choung S. Solanum tuberosum L. cv Hongyoung extract inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice. Mol. Med. Rep. 2016; 14(4): 3093-103. https://dx.doi.org/10.3892/mmr.2016.5595.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies